Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of aducanumab in mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia
2018-002102-31Phase 2Terminated
- Sponsor
- Biogen
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aducanumab in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease, sponsored by Biogen. Started Oct 2018; status: terminated.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2018-002102-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002102-31.